1. Home
  2. SNDX vs IGIC Comparison

SNDX vs IGIC Comparison

Compare SNDX & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • IGIC
  • Stock Information
  • Founded
  • SNDX 2005
  • IGIC 2001
  • Country
  • SNDX United States
  • IGIC Jordan
  • Employees
  • SNDX N/A
  • IGIC N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • IGIC Property-Casualty Insurers
  • Sector
  • SNDX Health Care
  • IGIC Finance
  • Exchange
  • SNDX Nasdaq
  • IGIC Nasdaq
  • Market Cap
  • SNDX 1.2B
  • IGIC 1.0B
  • IPO Year
  • SNDX 2016
  • IGIC N/A
  • Fundamental
  • Price
  • SNDX $14.34
  • IGIC $25.17
  • Analyst Decision
  • SNDX Strong Buy
  • IGIC Buy
  • Analyst Count
  • SNDX 10
  • IGIC 3
  • Target Price
  • SNDX $36.20
  • IGIC $23.67
  • AVG Volume (30 Days)
  • SNDX 2.1M
  • IGIC 77.2K
  • Earning Date
  • SNDX 02-25-2025
  • IGIC 02-25-2025
  • Dividend Yield
  • SNDX N/A
  • IGIC 0.39%
  • EPS Growth
  • SNDX N/A
  • IGIC 32.83
  • EPS
  • SNDX N/A
  • IGIC 3.04
  • Revenue
  • SNDX $16,000,000.00
  • IGIC $506,160,000.00
  • Revenue This Year
  • SNDX N/A
  • IGIC N/A
  • Revenue Next Year
  • SNDX N/A
  • IGIC $6.64
  • P/E Ratio
  • SNDX N/A
  • IGIC $8.17
  • Revenue Growth
  • SNDX N/A
  • IGIC 10.67
  • 52 Week Low
  • SNDX $12.06
  • IGIC $11.51
  • 52 Week High
  • SNDX $25.34
  • IGIC $27.00
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 54.69
  • IGIC 54.72
  • Support Level
  • SNDX $13.97
  • IGIC $23.87
  • Resistance Level
  • SNDX $13.16
  • IGIC $25.74
  • Average True Range (ATR)
  • SNDX 0.66
  • IGIC 0.66
  • MACD
  • SNDX 0.17
  • IGIC 0.11
  • Stochastic Oscillator
  • SNDX 85.39
  • IGIC 58.41

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

About IGIC International General Insurance Holdings Ltd.

International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.

Share on Social Networks: